IP Library Granted Patent US 9,381,202
Granted Patent B2
US 9,381,202 · App. 13/846,542 · Granted Jul 5, 2016

Salts of potassium ATP channel openers and uses thereof

Inventors: Neil M. Cowen (Carlsbad, CA); Khaled A. Yamout (Carlsbad, CA)
Assignee: ESSENTIALIS, INC.
A61K31/549A61K9/2086A61K31/54A61K45/06C07C209/68C07C213/08C07D285/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,202
App. No.
13/846,542
Granted
Jul 5, 2016
Kind
B2
Abstract

Provided are immediate or prolonged administration of certain salts of K ATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Claims (28)

1. A method for the preparation of a salt of a compound of Formula I comprising:

reacting one equivalent of a cation source selected from the group consisting of an alkali metal hydroxide or an organic cation source comprising an ammonium or at least one tertiary amine group with a compound of Formula I,

wherein:

R 1 is selected from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, cycloalkyl, and substituted cycloalkyl provided however that when R 1 is a substituted lower alkyl or a substituted cycloalkyl, then the substituent does not include an amino group;

R 2a is hydrogen;

X is a 1, 2 or 3 carbon atom chain, wherein each atom is optionally substituted with halogen, hydroxyl, lower alkyl, substituted lower alkyl, lower alkoxy, cycloalkyl, substituted cycloalkyl, or substituted lower alkoxy, provided however that when an atom of the chain is substituted with substituted lower alkyl, substituted lower alkoxy or substituted cycloalkyl, then the substituent does not include an amino group; and

ring B is polyunsaturated or aromatic;

said compound of Formula I is dissolved in a solvent selected from the group consisting of acetonitrile, low molecular weight ketones, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylformamide and n-methyl pyrrolidinone, and removing the solvent.

2. The method of claim 1 wherein said cation source is an organic cation source comprising an ammonium or at least one tertiary amine group.

3. The method of claim 1 wherein said cation source is choline hydroxide or hexamethyl hexamethylene diammonium dihydroxide.

4. The method of claim 3 wherein said solvent is selected from the group consisting of acetonitrile, low molecular weight ketones, tetrahydrofuran, and 2-methyl tetrahydrofuran.

5. The method of claim 3 wherein said cation source is choline hydroxide, and said solvent is selected from the group consisting of acetonitrile, low molecular weight ketones, tetrahydrofuran, and 2-methyl tetrahydrofuran.

6. The method of claim 3 wherein said compound of Formula I is dissolved in a solvent at a ratio of about 1 g compound of Formula I to about 1 to 5 mL solvent.

7. The method of claim 6 further comprising adding a co-solvent prior to the step of removing the solvent.

8. The method of claim 7 wherein said co-solvent is selected from the group consisting of methyl tert-butyl ether (MTBE), ethyl acetate (EtOAc), isopropanol (IPA), c-Hexane, heptane, toluene, dichloromethane (CH 2 Cl 2 ), and dioxane.

9. The method of claim 7 wherein said co-solvent is methyl tert-butyl ether (MTBE).

10. The method of claim 7 wherein the ratio of said solvent to said co-solvent is about 3:12-16 (solvent:co-solvent).

11. The method of claim 1 wherein said compound of Formula I is diazoxide.

12. The method of claim 11 wherein said solvent is selected from the group consisting of acetonitrile, low molecular weight ketones, and tetrahydrofuran.

13. The method of claim 11 wherein said cation source is choline hydroxide or hexamethyl hexamethylene diammonium dihydroxide.

14. The method of claim 13 wherein said solvent is selected from the group consisting of acetonitrile, low molecular weight ketones, tetrahydrofuran, and 2-methyl tetrahydrofuran.

15. The method of claim 13 wherein said cation source is choline hydroxide.

16. The method of claim 15 wherein said solvent is selected from the group consisting of acetonitrile, low molecular weight ketones, tetrahydrofuran, and 2-methyl tetrahydrofuran.

17. The method of claim 11 wherein diazoxide is dissolved in a solvent at a ratio of about 1 g diazoxide to about 1 to 5 mL solvent.

18. The method of claim 11 further comprising adding a co-solvent prior to the step of removing the solvent.

19. The method of claim 18 wherein said co-solvent is selected from the group consisting of methyl tert-butyl ether (MTBE), ethyl acetate (EtOAc), isopropanol (IPA), c-Hexane, heptane, toluene, dichloromethane (CH 2 Cl 2 ), and dioxane.

20. The method of claim 18 wherein said co-solvent is methyl tert-butyl ether (MTBE).

21. The method of claim 18 wherein the ratio of said solvent to said co-solvent is about 3:12-16 (solvent:co-solvent).

Assignments (6)
SECURITY INTEREST Recorded Jun 26, 2026
From: SOLENO THERAPEUTICS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 075106/0487 →
RELEASE OF SECURITY INTEREST (REEL 070494, FRAME 0042) Recorded May 19, 2026
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
Reel/Frame 075601/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2025
From: ESSENTIALIS, INC.
To: SOLENO THERAPEUTICS, INC.
Reel/Frame 073832/0312 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 12, 2025
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 070494/0042 →
SECURITY INTEREST Recorded Dec 17, 2024
From: SOLENO THERAPEUTICS, INC.; ESSENTIALIS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 069613/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: COWEN, NEIL M.; KASHKIN, KENNETH B.; YAMOUT, KHALED A.
To: ESSENTIALIS, INC.
Reel/Frame 042470/0234 →
Continuity (5)
Continuation 12819155 · Jun 18, 2010
Division 11614044 · Dec 20, 2006
Provisional Application 60854740 · Oct 27, 2006
Provisional Application 60756941 · Jan 5, 2006
Related Publication 20130225806A1 · Aug 29, 2013